Trending News

State Department Issues New, Immediate Requirement for Nonimmigrant Visa Applicants

Adjudicating Nonimmigrant Visa Applicants in Their Country of Residence — Implications for Employers and Employees

District Court Rejects First Amendment Challenge to California Climate Disclosure Requirements

This Week in 340B: August 5 – 11, 2025

DOL Resurrects PAID Program to Supervise Employers’ Self-Audits and Settlements of Potential FLSA and FMLA Violations

Trump Administration Issues AI Action Plan and AI Executive Orders

Winning the Race: America’s AI Action Plan

Innovation Over Regulation – Trump Unveils America’s AI Action Plan

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Posted On Wednesday, July 30, 2025
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Posted On Wednesday, July 30, 2025
FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers
Posted On Wednesday, July 30, 2025
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
Posted On Wednesday, July 30, 2025
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
Posted On Wednesday, July 30, 2025
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Posted On Wednesday, July 30, 2025
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Posted On Wednesday, July 30, 2025
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator
Posted On Wednesday, July 30, 2025
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Posted On Wednesday, July 30, 2025
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Posted On Wednesday, July 30, 2025
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Posted On Wednesday, July 30, 2025
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
Posted On Wednesday, July 30, 2025
Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy
Posted On Wednesday, July 30, 2025
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Posted On Wednesday, July 30, 2025
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
Posted On Wednesday, July 30, 2025
Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models
Posted On Wednesday, July 30, 2025
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
Posted On Wednesday, July 30, 2025
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
Posted On Wednesday, July 30, 2025
Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call
Posted On Wednesday, July 30, 2025
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Posted On Wednesday, July 30, 2025
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
Posted On Wednesday, July 30, 2025
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Posted On Wednesday, July 30, 2025
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
Posted On Wednesday, July 30, 2025
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Posted On Wednesday, July 30, 2025
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Posted On Wednesday, July 30, 2025

Print